RPRX logo

Royalty Pharma plc (RPRX) EBITDA

Annual EBITDA:

$1.29B-$199.71M(-13.38%)
December 31, 2024

Summary

  • As of today, RPRX annual EBITDA is $1.29 billion, with the most recent change of -$199.71 million (-13.38%) on December 31, 2024.
  • During the last 3 years, RPRX annual EBITDA has fallen by -$161.27 million (-11.09%).
  • RPRX annual EBITDA is now -51.18% below its all-time high of $2.65 billion, reached on December 31, 2019.

Performance

RPRX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

Quarterly EBITDA:

$428.43M+$218.63M(+104.21%)
September 30, 2025

Summary

  • As of today, RPRX quarterly EBITDA is $428.43 million, with the most recent change of +$218.63 million (+104.21%) on September 30, 2025.
  • Over the past year, RPRX quarterly EBITDA has dropped by -$306.64 million (-41.72%).
  • RPRX quarterly EBITDA is now -67.97% below its all-time high of $1.34 billion, reached on December 31, 2019.

Performance

RPRX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

TTM EBITDA:

$1.53B-$306.64M(-16.66%)
September 30, 2025

Summary

  • As of today, RPRX TTM EBITDA is $1.53 billion, with the most recent change of -$306.64 million (-16.66%) on September 30, 2025.
  • Over the past year, RPRX TTM EBITDA has dropped by -$10.52 million (-0.68%).
  • RPRX TTM EBITDA is now -42.31% below its all-time high of $2.66 billion, reached on June 30, 2020.

Performance

RPRX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRPRXincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

RPRX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-13.4%-41.7%-0.7%
3Y3 Years-11.1%+122.9%+60.7%
5Y5 Years-51.2%-17.0%-41.8%

RPRX EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-13.4%+39.2%-41.7%+680.7%-19.3%+65.2%
5Y5-Year-51.2%+39.2%-42.9%+680.7%-41.8%+65.2%
All-TimeAll-Time-51.2%+63.4%-68.0%+680.7%-42.3%+250.5%

RPRX EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
$428.43M(+104.2%)
$1.53B(-16.7%)
Jun 2025
-
$209.80M(-60.7%)
$1.84B(-3.1%)
Mar 2025
-
$534.18M(+48.0%)
$1.90B(+47.1%)
Dec 2024
$1.29B(-13.4%)
$361.00M(-50.9%)
$1.29B(-16.3%)
Sep 2024
-
$735.07M(+172.6%)
$1.54B(+60.8%)
Jun 2024
-
$269.63M(+465.5%)
$960.30M(+2.2%)
Mar 2024
-
-$73.77M(-112.0%)
$939.51M(-37.0%)
Dec 2023
$1.49B(+60.7%)
$613.00M(+304.8%)
$1.49B(+47.4%)
Sep 2023
-
$151.44M(-39.1%)
$1.01B(-3.9%)
Jun 2023
-
$248.84M(-48.0%)
$1.05B(-10.9%)
Mar 2023
-
$478.97M(+260.1%)
$1.18B(+27.3%)
Dec 2022
$928.56M(-36.1%)
$133.00M(-30.8%)
$928.39M(-2.7%)
Sep 2022
-
$192.21M(-49.1%)
$954.39M(-10.9%)
Jun 2022
-
$377.79M(+67.6%)
$1.07B(-25.8%)
Mar 2022
-
$225.39M(+41.8%)
$1.44B(-0.7%)
DateAnnualQuarterlyTTM
Dec 2021
$1.45B(-10.2%)
$159.00M(-48.5%)
$1.45B(-10.0%)
Sep 2021
-
$308.85M(-58.9%)
$1.61B(-11.4%)
Jun 2021
-
$750.68M(+219.5%)
$1.82B(+22.6%)
Mar 2021
-
$234.97M(-26.6%)
$1.49B(-8.2%)
Dec 2020
$1.62B(-38.9%)
$320.00M(-38.0%)
$1.62B(-38.6%)
Sep 2020
-
$516.36M(+24.4%)
$2.64B(-0.8%)
Jun 2020
-
$415.08M(+13.1%)
$2.66B(+3.2%)
Mar 2020
-
$367.16M(-72.6%)
$2.58B(-2.7%)
Dec 2019
$2.65B(+89.4%)
$1.34B(+148.5%)
$2.65B(+102.2%)
Sep 2019
-
$538.29M(+61.4%)
$1.31B(+69.8%)
Jun 2019
-
$333.59M(-23.8%)
$771.09M(+76.2%)
Mar 2019
-
$437.50M
$437.50M
Dec 2018
$1.40B(+43.7%)
-
-
Dec 2017
$972.96M(+23.0%)
-
-
Dec 2016
$791.08M(-8.3%)
-
-
Dec 2015
$862.44M
-
-

FAQ

  • What is Royalty Pharma plc annual EBITDA?
  • What is the all-time high annual EBITDA for Royalty Pharma plc?
  • What is Royalty Pharma plc annual EBITDA year-on-year change?
  • What is Royalty Pharma plc quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Royalty Pharma plc?
  • What is Royalty Pharma plc quarterly EBITDA year-on-year change?
  • What is Royalty Pharma plc TTM EBITDA?
  • What is the all-time high TTM EBITDA for Royalty Pharma plc?
  • What is Royalty Pharma plc TTM EBITDA year-on-year change?

What is Royalty Pharma plc annual EBITDA?

The current annual EBITDA of RPRX is $1.29B

What is the all-time high annual EBITDA for Royalty Pharma plc?

Royalty Pharma plc all-time high annual EBITDA is $2.65B

What is Royalty Pharma plc annual EBITDA year-on-year change?

Over the past year, RPRX annual EBITDA has changed by -$199.71M (-13.38%)

What is Royalty Pharma plc quarterly EBITDA?

The current quarterly EBITDA of RPRX is $428.43M

What is the all-time high quarterly EBITDA for Royalty Pharma plc?

Royalty Pharma plc all-time high quarterly EBITDA is $1.34B

What is Royalty Pharma plc quarterly EBITDA year-on-year change?

Over the past year, RPRX quarterly EBITDA has changed by -$306.64M (-41.72%)

What is Royalty Pharma plc TTM EBITDA?

The current TTM EBITDA of RPRX is $1.53B

What is the all-time high TTM EBITDA for Royalty Pharma plc?

Royalty Pharma plc all-time high TTM EBITDA is $2.66B

What is Royalty Pharma plc TTM EBITDA year-on-year change?

Over the past year, RPRX TTM EBITDA has changed by -$10.52M (-0.68%)
On this page